Renal cell carcinoma and the use of sorafenib

Therapeutics and Clinical Risk Management

Volumn 2, Issue 1, 2006, Pages 87-98

  Larkin, James M G ^a   Eisen, Tim ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Metastatic; Renal cell carcinoma; Sorafenib; Systemic therapy

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; ERLOTINIB; GEFITINIB; IMATINIB; INTERFERON; INTERLEUKIN 2; MONOCLONAL ANTIBODY; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; SORAFENIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; TRASTUZUMAB; VASCULOTROPIN;

ADVANCED CANCER; ALOPECIA; ANOREXIA; BONE MARROW SUPPRESSION; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; FATIGUE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; METASTASIS; NAUSEA; NONHUMAN; OVERALL SURVIVAL; PANCREATITIS; PATHOPHYSIOLOGY; REVIEW; SKIN TOXICITY; STOMATITIS; TREATMENT PLANNING; TUMOR VASCULARIZATION;

EID: 33745459794     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (109)

1. Atkins M, Regan M, McDermott D, et al. 2005. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res, 11:3714-21.
2. Atlas I, Mendelsohn J, Baselga J, et al. 1992. Growth regulation of human renal carcinoma cells: role of transforming growth factor alpha. Cancer Res, 52:3335-9.
3. Atzpodien J, Schmitt E, Gertenbach U, et al. 2005. Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer, 92:843-6.
4. Awada A, Hendlisz A, Gil T, et al. 2005. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer, 92:1855-61.
5. Beck SD, Patel MI, Snyder ME, et al. 2004. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol, 11:71-7.
6. Beer DG, Kardia SL, Huang CC, et al. 2002. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med, 8: 816-24.
7. Bhattacharjee A, Richards WG, Staunton J, et al. 2001. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A, 98:13790-5.
8. Branch H, Weirich G, Brieger J, et al. 2000. VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. Cancer Res, 60:1942-8.
9. Chang J, Powles TJ, Allred DC, et al. 1999. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol, 17:3058-63.
10. Cheville JC, Lohse CM, Zincke H, et al. 2003. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol, 27:612-24.
11. Clark JI, Atkins MB, Urba WJ, et al. 2003. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol, 21:3133-40.
12. Clark JW, Eder JP, Ryan D, et al. 2005. Safety and pharmacokinetics of the dual action raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractary solid tumors. Clin Cancer Res, 11:5472-80.
13. Clifford SC, Prowse AH, Affara NA, et al. 1998. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer, 22:200-9.
14. Coppin C, Porzsolt F, Awa A, et al. 2005. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev, (3):CD001425.
15. Cunningham D, Humblet Y, Siena S, et al. 2004. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med, 351:337-45.
16. Davies H, Bignell GR, Cox C, et al. 2002. Mutations of the BRAF gene in human cancer. Nature, 417:949-54.
17. Druker BJ, Talpaz M, Resta DJ, et al. 2001. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med, 344:1031-7.
18. Dulaimi E, Ibanez de Caceres I, Uzzo RG, et al. 2004. Promoter hypermethylation profile of kidney cancer. Clin Cancer Res, 10: 3972-9.
19. Escudier B, Szczylik C, Eisen T, et al. 2005a. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). ASCO Annual Meeting Proceedings; 2005 May 14-17; Orlando FL. J Clin Oncol, 23(16S):LBA4510.
20. Escudier B, Szczylik C, Eisen T, et al. 2005b. Randomized Phase III Trial of The Multi-kinase Inhibitor Sorafenib (BAY 43-9006) in Patients With Advanced RCC. Presented at ECCO; 2005 30 Oct-3 Nov; Paris, France.
21. Escudier B, Szczylik C, Eisen T, et al. 2005c. Randomized Phase III Trial of The Multi-kinase Inhibitor Sorafenib (BAY 43-9006) in Patients With Advanced RCC. Oral presentation. 41st ASCO Annual Meeting proceedings; May 2005 14-17; Orlando FL.
22. Faivre S, Delbaldo C, Vera K, et al. 2006. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol, 24:25-35.
23. Ferrara N, Gerber HP, LeCouter J. 2003. The biology of VEGF and its receptors. Nat Med, 9:669-76.
24. Ferrara N, Hillan KJ, Gerber HP, Novotny W. 2004. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov, 3:391-400.
25. Ficarra V, Schips L, Guille F, et al. 2005. Multiinstitutional European validation of the 2002 TNM staging system in conventional and papillary localized renal cell carcinoma. Cancer, 104:968-74.
26. Flanigan RC, Mickisch G, Sylvester R, et al. 2004. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol, 171:1071-6.
27. Flanigan RC, Salmon SE, Blumenstein BA, et al. 2001. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med, 345:1655-9.
28. Folkman J. 1972. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg, 175:409-16.
29. Fujita J, Kraus MH, Onoue H, et al. 1988. Activated H-ras oncogenes in human kidney tumors. Cancer Res, 48:5251-5.
30. Giaccone G, Herbst RS, Manegold C, et al. 2004. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol, 22:777-84.
31. Gleave ME, Elhilali M, Fradet Y, et al. 1998. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med, 338:1265-71.
32. Gomella LG, Sargent ER, Wade TP, et al. 1989. Expression of transforming growth factor alpha in normal human adult kidney and enhanced expression of transforming growth factors alpha and beta 1 in renal cell carcinoma. Cancer Res, 49:6972-5.
33. Gunningham SP, Currie MJ, Han C, et al. 2001. Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia. Cancer Res, 61:3206-11.
34. Harris DT. 1983. Hormonal therapy and chemotherapy of renal-cell carcinoma. Semin Oncol, 10:422-30.
35. Herbst RS, Giaccone G, Schiller JH, et al. 2004. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol, 22:785-94.
36. Herman JG, Latif F, Weng Y, et al. 1994. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA, 91:9700-4.
37. Horoszewicz JS, Murphy GP. 1989. An assessment of the current use of human interferons in therapy of urological cancers. J Urol, 142: 1173-80.
38. Iizuka N, Oka M, Yamada-Okabe H, et al. 2003. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet, 361: 923-9.
39. Iliopoulos O, Levy AP, Jiang C, et al. 1996. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A, 93:10595-9.
40. Kim WY, Kaelin WG. 2004. Role of VHL gene mutation in human cancer. J Clin Oncol, 22:4991-5004.
41. Kondo K, Yao M, Yoshida M, et al. 2002. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters. Genes Chromosomes Cancer, 34:58-68.
42. Kosari F, Parker AS, Kube DM, et al. 2005. Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness. Clin Cancer Res, 11:5128-39.
43. Kris MG, Natale RB, Herbst RS, et al. 2003. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA, 290:2149-58.
44. Landis SH, Murray T, Bolden S, Wingo PA. 1999. Cancer statistics, 1999. CA Cancer J Clin, 49:8-31, 1.
45. Lara PN, Jr., Quinn DI, Margolin K, et al. 2003. SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. Clin Cancer Res, 9:4772-81.
46. Larkin JM, Gore ME. 2005. The MRC randomised-controlled trial of interferon-alpha, interleukin-2 and 5-fluorouracil versus interferon-alpha alone in patients with advanced renal cell carcinoma (RE04): rationale and progress. Clin Oncol (R Coll Radiol), 17:319-21.
47. Latif F, Tory K, Gnarra J, et al. 1993. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science, 260:1317-20.
48. Lynch TJ, Bell DW, Sordella R, et al. 2004. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med, 350:2129-39.
49. Marais R, Light Y, Paterson HF, et al. 1997. Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J Biol Chem, 272:4378-83.
50. Messing EM, Manola J, Wilding G, et al. 2003. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol, 21:1214-22.
51. Michiels S, Koscielny S, Hill C. 2005. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet, 365: 488-92.
52. Mickisch GH, Garin A, van Poppel H, et al. 2001. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma:a randomised trial. Lancet, 358:966-70.
53. Minardi D, Lucarini G, Mazzucchelli R, et al. 2005. Prognostic role of Fuhrman grade and vascular endothelial growth factor in pT1a clear cell carcinoma in partial nephrectomy specimens. J Urol, 174: 1208-12.
54. Moore M, Hirte HW, Siu L, et al. 2005. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol, 16: 1688-94.
55. Motzer RJ, Bacik J, Mariani T, et al. 2002. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol, 20:2376-81.
56. Motzer RJ, Bacik J, Mazumdar M. 2004. Prognostic factors for survival of patients with stage IV renal cell carcinoma: memorial sloan-kettering cancer center experience. Clin Cancer Res, 10:6302S-3S.
57. Motzer RJ, Bacik J, Schwartz LH, et al. 2004. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol, 22:454-63.
58. Motzer RJ, Michaelson MD, Redman BG, et al. 2006. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol, 24:16-24.
59. [MRC] Medical Research Council Renal Cancer Collaborators. 1999. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet, 353:14-17.
60. Mydlo JH, Michaeli J, Cordon-Cardo C, et al. 1989. Expression of transforming growth factor alpha and epidermal growth factor receptor messenger RNA in neoplastic and nonneoplastic human kidney tissue. Cancer Res, 49:3407-11.
61. Na X, Wu G, Ryan CK, et al. 2003. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. J Urol, 170:588-92.
62. Nagy A, Balint I, Kovacs G. 2003. Frequent allelic changes at chromosome 7q34 but lack of mutation of the BRAF in papillary renal cell tumors. Int J Cancer, 106:980-1.
63. Namba Y, Kijima T, Yokota S, et al. 2004. Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases. Clin Lung Cancer, 6:123-8.
64. Ohh M, Park CW, Ivan M, et al. 2000. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol, 2:423-7.
65. Oka H, Chatani Y, Hoshino R, et al. 1995. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res, 55:4182-7.
66. Oliver RT, Nethersell AB, Bottomley JM. 1989. Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma. Br J Urol, 63:128-31.
67. Omuro AM, Kris MG, Miller VA, et al. 2005. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer, 103:2344-8.
68. Paez JG, Janne PA, Lee JC, et al. 2004. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 304:1497-500.
69. Pao W, Miller V, Zakowski M, et al. 2004. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A, 101:13306-11.
70. Parkin DM, Pisani P, Ferlay J. 1999. Global cancer statistics. CA Cancer J Clin, 49:33-64, 1.
71. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. 2005. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med, 353:1659-72.
72. Pizzocaro G, Piva L, Colavita M, et al. 2001. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol, 19:425-31.
73. Pomeroy SL, Tamayo P, Gaasenbeek M, et al. 2002. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature, 415:436-42.
74. Potti A, George DJ. 2004. Tyrosine kinase inhibitors in renal cell carcinoma. Clin Cancer Res, 10:6371S-6S.
75. Pyrhonen S, Salminen E, Ruutu M, et al. 1999. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol, 17:2859-67.
76. Ramaswamy S, Ross KN, Lander ES, Golub TR. 2003. A molecular signature of metastasis in primary solid tumors. Nat Genet, 33: 49-54.
77. Ramp U, Reinecke P, Gabbert HE, Gerharz CD. 2000. Differential response to transforming growth factor (TGF)-alpha and fibroblast growth factor (FGF) in human renal cell carcinomas of the clear cell and papillary types. Eur J Cancer, 36:932-41.
78. Ratain MJ, Eisen T, Stadler WM, et al. 2005. Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). 41st ASCO Annual Meeting Proceedings; 2005 May 14-17; Orlando FL. J Clin Oncol, 23(16S):4544.
79. Robert C, Soria JC, Spatz A, et al. 2005. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol, 6:491-500.
80. Romond EH, Perez EA, Bryant J, et al. 2005. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med, 353:1673-84.
81. Rosenberg SA, Yang JC, White DE, Steinberg SM. 1998. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg, 228:307-19.
82. Rosenwald A, Wright G, Chan WC, et al. 2002. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med, 346:1937-47.
83. Rosner GL, Stadler W, Ratain MJ. 2002. Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol, 20:4478-84.
84. Schlessinger J. 2000. Cell signaling by receptor tyrosine kinases. Cell, 103:211-25.
85. Selli C, Hinshaw WM, Woodard BH, Paulson DF. 1983. Stratification of risk factors in renal cell carcinoma. Cancer, 52:899-903.
86. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. 2005. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med, 353: 123-32.
87. Slamon DJ, Leyland-Jones B, Shak S, et al. 2001. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 344:783-92.
88. Sordella R, Bell DW, Haber DA, Settleman J. 2004. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science, 305:1163-7.
89. Spigel DR, Hainsworth JD, Sosman JA. 2005. Bevacizumab and erlotinib in the treatment of patients with metastatic renal carcinoma (RCC): Update of a phase II multicenter trial. ASCO Annual Meeting Proceedings. J Clin Oncol, 23(16S):4540.
90. Sridhar SS, Hedley D, Siu LL. 2005. Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther, 4:677-85.
91. Stadler WM, Rosner G, Small E, et al. 2005. Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma - CALGB 69901. J Clin Oncol, 23:3726-32.
92. Strumberg D, Richly H, Hilger RA, et al. 2005. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol, 23:965-72.
93. Strumberg D, Voliotis D, Moeller JG, et al. 2002. Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors. Int J Clin Pharmacol Ther, 40:580-1.
94. Sulzbacher I, Birner P, Traxler M, et al. 2003. Expression of platelet-derived growth factor-alpha alpha receptor is associated with tumor progression in clear cell renal cell carcinoma. Am J Clin Pathol, 120:107-12.
95. Toms JR, editor. 2004. CancerStats Monograph. London: Cancer Research UK, 2004.
96. Turner KJ, Moore JW, Jones A, et al. 2002. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res, 62:2957-61.
97. Uhlman DL, Nguyen P, Manivel JC, et al. 1995. Epidermal growth factor receptor and transforming growth factor alpha expression in papillary and nonpapillary renal cell carcinoma: correlation with metastatic behavior and prognosis. Clin Cancer Res, 1:913-20.
98. van de Vijver MJ, He YD, van't Veer LJ, et al. 2002. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med, 347:1999-2009.
99. van Oosterom AT, Judson I, Verweij J, et al. 2001. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet, 358:1421-3.
100. Wan PT, Garnett MJ, Roe SM, et al. 2004. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of BRAF. Cell, 116:855-67.
101. Wilhelm SM, Carter C, Tang L, et al. 2004. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res, 64:7099-109.
102. Xu L, Tong R, Cochran DM, Jain RK. 2005. Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model. Cancer Res, 65:5711-19.
103. Yagoda A, Bander NH. 1989. Failure of cytotoxic chemotherapy, 1983-1988, and the emerging role of monoclonal antibodies for renal cancer. Urol Int, 44:338-45.
104. Yang JC, Haworth L, Sherry RM, et al. 2003. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med, 349:427-34.
105. Yang XJ, Tan MH, Kim HL, et al. 2005. A molecular classification of papillary renal cell carcinoma. Cancer Res, 65:5628-37.
106. Yao M, Yoshida M, Kishida T, et al, 2002. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst, 94:1569-75.
107. Yeoh EJ, Ross ME, Shurtleff SA, et al. 2002. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell, 1:133-43.
108. Yildiz E, Gokce G, Kilicarslan H, et al. 2004. Prognostic value of the expression of Ki-67, CD44 and vascular endothelial growth factor, and microvessel invasion, in renal cell carcinoma. BJU Int, 93: 1087-93.
109. Zalcberg JR, Verweij J, Casali PG, et al. 2005. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800mg after progression on 400mg. Eur J Cancer, 41:1751-7.